Clinical studies investigating the effects of blocking CTLA‐4 and PD‐1/PD‐L1 have yielded exceptionally promising results in patients with advanced melanoma and other cancers, including RCC 8. This evidence concerns the gene CTLA4 and renal cell carcinoma.